Clinical context Statins are used for the primary and secondary prevention of cardiovascular disease and are among the most commonly prescribed medicines
Semaglutide is approved as Ozempic (diabetes, December 2017), Wegovy (obesity, June 2021), and, in oral form, the Ozempic pill (diabetes, 2026, which reformulated and renamed Rybelsus) and the Wegovy pill (weight, December 2025)
EPIDEMIOLOGY AND DISEASE BURDEN OF MASLD/MASH MASLD is estimated to impact around 32.4% of adults across the world and is currently considered the leading chronic liver disease globally, with estimates exceeding one billion individuals affected [13,14]
Adding GIP enhances fat metabolism and improves insulin sensitivity, which is why tirzepatide outperforms semaglutide on weight loss